CR20110269A - Lactamas como inhibidores de beta secretasa - Google Patents

Lactamas como inhibidores de beta secretasa

Info

Publication number
CR20110269A
CR20110269A CR20110269A CR20110269A CR20110269A CR 20110269 A CR20110269 A CR 20110269A CR 20110269 A CR20110269 A CR 20110269A CR 20110269 A CR20110269 A CR 20110269A CR 20110269 A CR20110269 A CR 20110269A
Authority
CR
Costa Rica
Prior art keywords
secretasa
inhibitors
beta
react
compounds
Prior art date
Application number
CR20110269A
Other languages
English (en)
Inventor
Michael Aaron Brodney
Ivan Viktorovich Efremov
Christopher John Helal
Brian Thomas O'neill
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41481076&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CR20110269(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer filed Critical Pfizer
Publication of CR20110269A publication Critical patent/CR20110269A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Psychology (AREA)
  • Hematology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Anesthesiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Otolaryngology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se desvelan compuestos y sales farmacéuticamente aceptables de los compuestos, en los que los compuestos tienen la estructura de la Fórmula I, como se define en la memoria descriptiva. También se desvelan composiciones farmacéuticas, procedimientos de tratamiento, procedimientos de síntesis e intermedios correspondientes.
CR20110269A 2008-11-23 2011-05-23 Lactamas como inhibidores de beta secretasa CR20110269A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US11722508P 2008-11-23 2008-11-23

Publications (1)

Publication Number Publication Date
CR20110269A true CR20110269A (es) 2011-07-04

Family

ID=41481076

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20110269A CR20110269A (es) 2008-11-23 2011-05-23 Lactamas como inhibidores de beta secretasa

Country Status (28)

Country Link
US (1) US20110224231A1 (es)
EP (1) EP2370439A1 (es)
JP (2) JP4932065B2 (es)
KR (1) KR20110086769A (es)
CN (1) CN102317289A (es)
AP (1) AP2011005725A0 (es)
AU (1) AU2009318855A1 (es)
BR (1) BRPI0922799A2 (es)
CA (1) CA2743584A1 (es)
CL (1) CL2011001147A1 (es)
CO (1) CO6361924A2 (es)
CR (1) CR20110269A (es)
CU (1) CU20110113A7 (es)
DO (1) DOP2011000134A (es)
EA (1) EA201170722A1 (es)
EC (1) ECSP11011073A (es)
GE (1) GEP20135806B (es)
IL (1) IL212869A0 (es)
MA (1) MA32929B1 (es)
MX (1) MX2011005346A (es)
NI (1) NI201100096A (es)
NZ (1) NZ592823A (es)
PE (1) PE20110777A1 (es)
SV (1) SV2011003916A (es)
TN (1) TN2011000252A1 (es)
UA (1) UA99787C2 (es)
WO (1) WO2010058333A1 (es)
ZA (1) ZA201103738B (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR074466A1 (es) 2008-12-05 2011-01-19 Sanofi Aventis Piperidina espiro pirrolidinona y piperidinona sustituidas y su uso terapeutico en enfermedades mediadas por la modulacion de los receptores h3.
KR101908255B1 (ko) 2009-03-13 2018-10-15 비타이 파마슈티컬즈, 인코포레이티드 베타세크리타아제 저해제
MX2012002993A (es) 2009-09-11 2012-04-19 Probiodrug Ag Derivados heterociclicos como inhibidores de ciclasa glutaminilo.
CN106905215B (zh) 2011-01-25 2021-10-01 拜耳知识产权有限责任公司 制备1-h-吡咯烷-2,4-二酮衍生物的方法
WO2012172449A1 (en) 2011-06-13 2012-12-20 Pfizer Inc. Lactams as beta secretase inhibitors
TWI557112B (zh) * 2012-03-05 2016-11-11 百靈佳殷格翰國際股份有限公司 β－分泌酶抑制劑
US9290477B2 (en) 2012-09-28 2016-03-22 Vitae Pharmaceuticals, Inc. Inhibitors of β-secretase
WO2016008064A1 (en) * 2014-07-14 2016-01-21 Merck Sharp & Dohme Corp. Inhibitors of renal outer medullary potassium channel
MX2017000634A (es) * 2014-07-14 2017-05-01 Merck Sharp & Dohme Inhibidores del canal de potasio medularmente externo renal.
US10752588B2 (en) 2014-12-19 2020-08-25 The Broad Institute, Inc. Dopamine D2 receptor ligands
EP3233077B1 (en) 2014-12-19 2026-05-06 The Broad Institute, Inc. Dopamine d2 receptor ligands
PL3461819T3 (pl) 2017-09-29 2020-11-30 Probiodrug Ag Inhibitory cyklazy glutaminylowej
CN113045484B (zh) * 2019-12-27 2024-01-26 南京药石科技股份有限公司 一种2-氨基-2-(1-甲基-4-哌啶基)丙烷-1-醇的制备方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4876260A (en) * 1987-10-28 1989-10-24 State Of Israel, Israel Institute Of Biological Research Oxathiolanes
US6262066B1 (en) * 1998-07-27 2001-07-17 Schering Corporation High affinity ligands for nociceptin receptor ORL-1
FR2824901B1 (fr) * 2001-05-21 2003-09-12 Poudres & Explosifs Ste Nale Procede et installation de destruction de fusee montee sur une munition
JP2007515425A (ja) * 2003-12-22 2007-06-14 シェーリング　コーポレイション 医薬組成物
CA2554920C (en) * 2004-02-17 2011-12-06 Herm. Sprenger Gmbh & Co. Kg Double-jointed bit for horses
WO2006041830A2 (en) * 2004-10-07 2006-04-20 Merck & Co., Inc. Cgrp receptor antagonists
CA2583342A1 (en) * 2004-10-13 2006-04-27 Merck And Co., Inc. Spiropiperidine compounds useful as beta-secretase inhibitors for the treatment of alzhermer's disease
GB0504556D0 (en) * 2005-03-04 2005-04-13 Pfizer Ltd Novel pharmaceuticals
US20080234252A1 (en) * 2005-05-18 2008-09-25 Pfizer Inc Compounds Useful in Therapy
US8211904B2 (en) * 2005-07-18 2012-07-03 Merck, Sharp & Dohme Corp. Spiropiperidine beta-secretase inhibitors for the treatment of alzheimer's disease
WO2007035139A1 (en) * 2005-09-20 2007-03-29 Sca Hygiene Products Ab Dispenser
US7985746B2 (en) * 2006-05-26 2011-07-26 Eisai R&D Management Co., Ltd. Imidazoazepinone compounds
WO2007139813A1 (en) * 2006-05-26 2007-12-06 Eisai R&D Management Co., Ltd Imidazoazephinone compounds
WO2007143847A1 (en) * 2006-06-14 2007-12-21 Virochem Pharma Inc. Spirotropane compounds
AU2007293416A1 (en) * 2006-09-07 2008-03-13 Merck & Co., Inc. Spiropiperidine beta-secretase inhibitors for the treatment of Alzheimer's disease
EP2073635B1 (en) * 2006-10-06 2012-03-21 Merck Sharp & Dohme Corp. Macrocyclic spiropiperidine beta-secretase inhibitors for the treatment of alzheimer's disease
ATE538651T1 (de) * 2006-10-30 2012-01-15 Merck Sharp & Dohme Spiropiperidininhibitoren von beta-secretase zur behandlung von alzheimer-krankheit

Also Published As

Publication number Publication date
MA32929B1 (fr) 2012-01-02
CA2743584A1 (en) 2010-05-27
DOP2011000134A (es) 2011-07-31
JP2012107029A (ja) 2012-06-07
EA201170722A1 (ru) 2011-10-31
GEP20135806B (en) 2013-04-10
CO6361924A2 (es) 2012-01-20
TN2011000252A1 (fr) 2012-12-17
ECSP11011073A (es) 2011-06-30
AU2009318855A1 (en) 2010-05-27
CU20110113A7 (es) 2012-01-31
BRPI0922799A2 (pt) 2019-09-24
JP4932065B2 (ja) 2012-05-16
CN102317289A (zh) 2012-01-11
PE20110777A1 (es) 2011-10-29
CL2011001147A1 (es) 2011-09-30
SV2011003916A (es) 2011-07-28
JP2012509310A (ja) 2012-04-19
AP2011005725A0 (en) 2011-06-30
ZA201103738B (en) 2012-01-25
EP2370439A1 (en) 2011-10-05
WO2010058333A1 (en) 2010-05-27
US20110224231A1 (en) 2011-09-15
NI201100096A (es) 2011-10-31
UA99787C2 (en) 2012-09-25
IL212869A0 (en) 2011-07-31
MX2011005346A (es) 2011-06-16
KR20110086769A (ko) 2011-07-29
NZ592823A (en) 2012-12-21

Similar Documents

Publication Publication Date Title
UY31189A1 (es) Compuestos heterocíclicos
CO6361924A2 (es) Nuevas lactamas como inhibidores de beta secretasa
UY30500A1 (es) Compuestos de azabencimidazolilo
UY32977A (es) Novedosos compuestos como inhibidores de la caseina quinasa
UY30498A1 (es) Nueva clase de compuestos de benzimidazolilo, sus sales, composiciones farmacéuticas conteniéndolos y aplicaciones
CO6470898A2 (es) Aril-piridinas como inhibidoras de sintasa de aldosterona
CR20110680A (es) Sulfonamidas heterociclicas, usos y composiciones farmacéuticas de las mismas
CU20110145A7 (es) Derivados de sulfonamida
ECSP11011411A (es) Derivados de prolina como inhibidores de catepsina
UY33779A (es) ?2-(fenilamino)-1H-bencimidazol-5-carboxamidas novedosas?
SV2011004077A (es) Derivados aminobutiricos sustituidos como inhibidores de neprilisina
CU20110235A7 (es) Derivados de imidazolidin-2-ona 1,3-disustituida como inhibidores de cyp17
UY33075A (es) Derivados de ciclohexano y usos de los mismos
CR20140399A (es) Pirrolidina-2-carboxamidas sustituidas
CO6741154A2 (es) Compuestos de triazolopiridina
GT200900309A (es) Derivados de 7-alquinil-1,8-naftiridonas, su preparacion y su aplicacion en terapeutica
CO6321280A2 (es) Nueva clase espiro piperidinas para el tratamiento de enfermedades neurodegenerativas
EA201290229A1 (ru) Производные спиролактама и их применение
UY32520A (es) Compuestos que tienen actividad agonista del receptor de glucocorticoesteroides
GT201300067A (es) Nuevos derivados dihidrobenzoxatiazepinas. su procedimiento de preparacion y las composiciones farmaceuticas que los
CU20100210A7 (es) Nueva clase de espiro piperidinas para el tratamiento de enfermedades neurodegenerativas
CY1115284T1 (el) Αρυλ πυριδινη ως αναστολεας της συνθασης της αλδοστερονης
HN2011002992A (es) Aril-piridinas como inhibidoras de sintasa de aldosterona

Legal Events

Date Code Title Description
FA Abandonment or withdrawal (granting procedure)